SARASOTA (Jan. 25, 2017) – Sarasota Memorial Hospital is among the first in Florida to offer high-risk patients a less invasive treatment for carotid stenosis – the buildup of plaque inside the carotid arteries that can lead to potentially disabling strokes and death.
Recently cleared by the FDA for the treatment of high-risk patients who have suffered symptoms of a warning stroke (TIA), TransCarotid Artery Revascularization (TCAR) is a new endovascular procedure that potentially avoids some of the complications that may occur with current treatment options.
At this time, Silk Road Medical’s ENROUTE Transcarotid Neuroprotection and Stent System is the only device currently approved for TCAR procedures by the FDA.
Read More: http://www.smh.com/Home/News-Events/Release/sarasota-memorial-hospital-among-first-to-offer-innovative-treatment-for-carotid-artery-disease
Via: PE HUB Network
SAN DIEGO, Jan. 20, 2017 /PRNewswire/ — Accriva Diagnostics, a Warburg Pincus portfolio company, announced today the definitive agreement with Werfen, a privately held medical diagnostics firm headquartered in Barcelona, Spain, and its subsidiary Instrumentation Laboratory (IL) headquartered in Bedford, MA, whereby Werfen and IL have acquired all shares of Accriva. The transaction was successfully closed on January 19, 2017.
OncoMed Initiates Enrollment of Phase 1b Clinical Trial of Brontictuzumab for the Treatment of Metastatic Colorectal Cancer Patients
REDWOOD CITY, Calif., Jan. 20, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced dosing of the first patient in a Phase 1b clinical trial of brontictuzumab (anti-Notch1, OMP-52M51) plus chemotherapy in patients with metastatic colorectal cancer.
Remedy Pharmaceuticals’ CIRARA Granted Orphan Drug Designation For Treatment of Severe Cerebral Edema Caused By Acute Ischemic Stroke
Via: Yahoo! Finance
NEW YORK--(BUSINESS WIRE)--
Omada Health has announced five new senior hires, most notably a new chief medical officer, Dr. Paul Chew, who previously served as senior VP and global chief medical officer at Sanofi. The company also announced the hire of Tom Schoenherr as chief commercial officer, a position he previously held at Counsyl.
Omada Health has accomplished a rare feat in the crowded world of digital health hopefuls: it's backed up lofty claims with actual results, helping the company score federal government reimbursements for its high-tech diabetes prevention program. Now, Omada is taking on some major biopharma talent as it heads into 2017 with the goal of becoming a go-to "digital therapeutics" option.
Via: Philly Voice
Vascular surgeons at Thomas Jefferson University Hospital will become the first in Philadelphia to perform a recently post-clinical trial approved procedure to treat carotid artery disease, a condition that annually affects more than 300,000 people in the United States.
Enters 2017 with $184.6 Million in Cash
REDWOOD CITY, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today pre-announced its 2016 year-end cash balance and reviewed key anticipated events for 2017.
OncoMed Initiates Enrollment of Phase 1b Clinical Trial of Anti-DLL4/VEGF Bispecific Antibody as Second-line Treatment for Metastatic Colorectal Cancer Patients
REDWOOD CITY, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced dosing of the first patient in a Phase 1b clinical trial of anti-DLL4/VEGF bispecific antibody (OMP-305B83) plus chemotherapy in patients with second-line metastatic colorectal cancer.
Outcomes of a Digital Health Program With Human Coaching for Diabetes Risk Reduction in a Medicare Population